(Q36808057)

English

Donepezil: an update

scientific article published on May 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

1 reference

Europe PubMed Central

Donepezil: an update (English)

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

1

object named as

Ben Seltzer

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

language of work or name

0 references

publication date

1 May 2007

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

Expert Opinion on Pharmacotherapy

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

1011-1023

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Donepezil: a review

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Donepezil: a clinical review of current and emerging indications

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

An Estimate of the Worldwide Prevalence and Direct Costs of Dementia in 2003

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

The magnitude of dementia occurrence in the world

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Global prevalence of dementia: a Delphi consensus study

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Neuroprotective effects of huperzine A: new therapeutic targets for neurodegenerative disease.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Molecular biology and genetics of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Immunology and immunotherapy of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Development of BACE1 inhibitors for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Inhibition of gamma-secretase as a therapeutic intervention for Alzheimer's disease: prospects, limitations and strategies

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

The development of anti-amyloid therapy for Alzheimer's disease : from secretase modulators to polymerisation inhibitors

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

The cholinergic hypothesis of geriatric memory dysfunction

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Alzheimer's disease. Correlation of cortical choline acetyltransferase activity with the severity of dementia and histological abnormalities.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

RBC cholinesterase inhibition: a useful surrogate marker for cholinesterase inhibitor activity in Alzheimer disease therapy?

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

PET imaging of brain acetylcholinesterase using [11C]CP-126,998, a brain selective enzyme inhibitor

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Global change assessments in anti-Alzheimer clinical drug trials.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

“Mini-mental state”

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

The effects of donepezil in Alzheimer's disease - results from a multinational trial.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Regulatory aspects of vascular dementia in the United States.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

The evaluation of disease modifying therapies in Alzheimer's disease: a regulatory viewpoint

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Do cholinergic therapies have disease-modifying effects in Alzheimer's disease?

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Cholinergic markers in elderly patients with early signs of Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Loss of basal forebrain P75(NTR) immunoreactivity in subjects with mild cognitive impairment and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Cholinergic treatment: what are the early neuropathological targets?

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Vitamin E and donepezil for the treatment of mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Protective effect of donepezil against Abeta(1-40) neurotoxicity in rat septal neurons

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Nicotinic receptor-mediated protection against beta-amyloid neurotoxicity

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Acetylcholinesterase inhibitors used in treatment of Alzheimer's disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Acetylcholinesterase imaging: its use in therapy evaluation and drug design

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Efficacy of proton magnetic resonance spectroscopy in neurological diagnosis and neurotherapeutic decision making

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Peripheral cytokine release in Alzheimer patients: correlation with disease severity

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Randomized, Placebo-Controlled Trial of the Effects of Donepezil on Neuronal Markers and Hippocampal Volumes in Alzheimer’s Disease

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Changes in the rCBF images of patients with Alzheimer's disease receiving Donepezil therapy.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Changes in the activity and protein levels of CSF acetylcholinesterases in relation to cognitive function of patients with mild Alzheimer's disease following chronic donepezil treatment.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Pharmacokinetic and pharmacodynamic profile of donepezil HCl following single oral doses

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Pharmacokinetic and pharmacodynamic profile of donepezil HCl following multiple oral doses

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Metabolism and elimination of 14C-donepezil in healthy volunteers: a single-dose study

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Sex influences on cholinesterase inhibitor treatment in elderly individuals with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Steady-state pharmacokinetics, pharmacodynamics and tolerability of donepezil hydrochloride in hepatically impaired patients

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Steady-state pharmacokinetics and safety of donepezil HCl in subjects with moderately impaired renal function

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Mild cognitive impairment: clinical characterization and outcome

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Specificity, sensitivity, and predictive value of apolipoprotein-E genotyping for sporadic Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Observations on the brains of demented old people

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Donepezil in vascular dementia: a randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Donepezil in vascular dementia: combined analysis of two large-scale clinical trials

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Cognitive, global, and functional benefits of donepezil in Alzheimer's disease and vascular dementia: results from large-scale clinical trials

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Classification of vascular dementia in the Cardiovascular Health Study Cognition Study.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Early and widespread cholinergic losses differentiate dementia with Lewy bodies from Alzheimer disease

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Rivastigmine for dementia associated with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Efficacy and safety of donepezil in patients with dementia with Lewy bodies: preliminary findings from an open-label study.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

A comparison of the efficacy of donepezil in Parkinson's disease with dementia and dementia with Lewy bodies.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Histopathological changes underlying frontotemporal lobar degeneration with clinicopathological correlation

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

In vivo cholinergic circuit evaluation in frontotemporal and Alzheimer dementias.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Rivastigmine in frontotemporal dementia: an open-label study.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease--pilot study.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Dramatic improvement in Down syndrome-associated cognitive impairment with donepezil

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Effects of Donepezil on Cognitive Functioning in Down Syndrome

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Effects of donepezil on memory and cognition in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Donepezil in the treatment of ADHD-like symptoms in youths with pervasive developmental disorder: a case series

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

A retrospective open trial of adjunctive donepezil in children and adolescents with autistic disorder

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Cholinergic augmentation with donepezil enhances recovery in short-term memory and sustained attention after traumatic brain injury

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Central acetylcholinesterase inhibitors in the treatment of chronic traumatic brain injury-clinical experience in 111 patients

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Efficacy and tolerability of low-dose donepezil in schizophrenia

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Caregiver-specific outcomes in antidementia clinical drug trials: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Impact of donepezil treatment for Alzheimer's disease on caregiver time

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Economic evaluation of donepezil in moderate to severe Alzheimer disease

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer's disease: a Markov model.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

An observational clinical study of the efficacy and tolerability of donepezil in the treatment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

A Large, Community-Based, Open-Label Trial of Donepezil in the Treatment of Alzheimer’s Disease

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Donepezil for Alzheimer's disease in clinical practice--The DONALD Study. A multicenter 24-week clinical trial in Germany

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Assessing therapeutic efficacy in a progressive disease: a study of donepezil in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Effect of donepezil in patients with Alzheimer's disease previously untreated or treated with memantine or nootropic agents in Germany: an observational study

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Apolipoprotein E epsilon4 allele differentiates the clinical response to donepezil in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Presence or absence of at least one epsilon 4 allele and gender are not predictive for the response to donepezil treatment in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Detecting effects of donepezil on visual selective attention using signal detection parameters in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Cholinergic enhancement of frontal lobe activity in mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

The safety and tolerability of donepezil in patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Galantamine extended release.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Guidelines for the treatment of Alzheimer's disease from the Italian Association of Psychogeriatrics

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

Identifiers

10.1517/14656566.8.7.1011

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36808057&oldid=2056640490"